HuMax-CD4 (zanolimumab) / Emergent Biosolutions - LARVOL DELTA

Targeted T-cell depletion with 211At-labeled antibodies enables rapid, non-genotoxic lymphodepletion in nonhuman primates (ASGCT 2026) - "Introduction Lymphodepletion for CAR T-cell therapy currently relies on cyclophosphamide and fludarabine regimens that are lengthy, genotoxic, and associated with prolonged cytopenias...Methods Ab targeting CD3 (clone SP34-R1), CD4 (clone zanolimumab, “Zn”), and an irrelevant isotype control Ab (clone DSPR1) were conjugated to a boron cage pendant group (B10) to enhance 211 At radiolabeling...(A) Total CD3+ T-cells and (B) CD4+ T-cells were quantified longitudinally in blood. Data shown represent the 0.5 mg/kg dose of each antibody."

Bone Marrow Transplantation • Fibrosis • Hematological Disorders • Hematological Malignancies • Human Immunodeficiency Virus • Immunology • Infectious Disease • Leukemia • Lymphoma • Neutropenia • Solid Organ Transplantation • Thrombocytopenia

COMPARATIVE EFFICACY OF THERAPEUTIC APPROACHES IN RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS (EHA 2025) - "This meta-analysis evaluates the efficacy of various therapies for RR-PTCL, including Epigenetic modifiers (HDIs, DNA methyltransferase inhibitors, EZH1/2 inhibitors), Small molecule inhibitors (targeting PI3K/AKT/mTOR, JAK/STAT, ALK, aurora kinase, farnesyl transferase), Combination therapies (various multi-class drug combinations), Pralatrexate-based regimens, monoclonal antibodies (e.g., Pembrolizumab, Alemtuzumab, Zanolimumab, etc.) and Others (Acimtamig, CAR T-cell therapy, etc.). This analysis suggests that combination therapies had the highest response rates, with SMI and pralatrexate-based therapies showing the longest OS. Other cytotoxic chemotherapy-based regimens had the lowest effectiveness, which suggests that combined targeted no-cytotoxic treatment regimens should be further studied in R/R PTCL. Outcomes continue to be poor, and clinical trials with novel treatment strategies should be prioritized"

Retrospective data • Review • Hematological Malignancies • Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • EZH2